Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

Endeavour Group: Party Time

Oct 20 2022

Consumers are back in force, drinking and eating and losing money in pubs. Will it last?


Metcash Spending More To Accelerate Growth

Oct 19 2022

Metcash is ramping up capital expenditure as the new CEO seeks to reinvigorate the MFuture strategy


Australian Banks: In A Fix

Oct 19 2022

The RBA believes Australians are well-placed to weather mortgage stress from higher rates, but risks will increase sharply when fixed interest loans start rolling off


Australian Listed Investment Company Review FY22

Oct 17 2022

Independent Investment Research reviews the financial and dividend performance of listed investment companies in FY22.


Australian Listed Investment Company Report October 2022

Oct 10 2022

Independent Investment Research updates developments among Australia’s listed investment companies and provides comparative data


September In Review: All ASX Sectors Lose Ground

Oct 06 2022

All sectors of the Australian stock market lost ground in September as global recession fears and higher bond yields weighed, resulting in a -6.2% loss for the ASX200


Weaker Oz House Prices To Reverberate In 2023

Oct 05 2022

Australian housing prices are forecast to continue declining as rising interest rates have yet to impact in full, with consequences for the broader economy in 2023


Premier Investments: Peter Alexander Joins Smiggle

Oct 04 2022

Brokers remain upbeat on Premier Investments following FY22 results though remain wary of the uncertain macroeconomic backdrop


FNArena Corporate Results Monitor – 03-10-2022

Oct 03 2022

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments


Brokers Review Prospects For CSL

Sep 30 2022

Brokers remain generally upbeat on CSL and focus upon the earnings contribution from the Vifor Pharma acquisition 



Analyse The Market From A Different Angle